GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » FCF Yield %

Athersys (Athersys) FCF Yield % : -9,084.93 (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Athersys FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Athersys's Trailing 12-Month Free Cash Flow is $-24.71 Mil, and Market Cap is $0.27 Mil. Therefore, Athersys's FCF Yield % for today is -9,084.93%.

The historical rank and industry rank for Athersys's FCF Yield % or its related term are showing as below:

ATHXQ' s FCF Yield % Range Over the Past 10 Years
Min: -22930.49   Med: -0.67   Max: -0.15
Current: -9084.93


During the past 13 years, the highest FCF Yield % of Athersys was -0.15%. The lowest was -22930.49%. And the median was -0.67%.

ATHXQ's FCF Yield % is ranked worse than
99.55% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs ATHXQ: -9084.93

Athersys's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.


Athersys FCF Yield % Historical Data

The historical data trend for Athersys's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys FCF Yield % Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.16 -18.27 -17.82 -35.38 -392.81

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -177.25 -273.04 -105.17 -96.55 -133.09

Competitive Comparison of Athersys's FCF Yield %

For the Biotechnology subindustry, Athersys's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Athersys's FCF Yield % falls into.



Athersys FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Athersys's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-59.347 / 15.108408
=-392.81%

Athersys's annualized FCF Yield % for the quarter that ended in Sep. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.847 * 4 / 11.56230464
=-133.09%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athersys FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Athersys FCF Yield % Related Terms

Thank you for viewing the detailed overview of Athersys's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (Athersys) Business Description

Traded in Other Exchanges
N/A
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Executives
Neema Mayhugh director 3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan director 100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo director, officer: Chief Executive Officer ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen officer: Chief Operating Officer 16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado officer: Interim, CFO 485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann officer: President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington director, officer: Chief Scientific Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell officer: Vice President 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin director 3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah director ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub director
Tadahisa Kagimoto director, 10 percent owner HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115

Athersys (Athersys) Headlines

From GuruFocus

Athersys Appoints Joseph Nolan to Its Board of Directors

By Business Wire Business Wire 01-05-2023